The T393C polymorphism of GNAS1 is a predictor for relapse and survival in resectable non-small cell lung cancer

详细信息    查看全文

• 作者：Faik Gü ; ntac Uzunoglu¹ ; Asmus Heumann¹ ; Safije Musici ; Asad Kutup ; Alexandra Koenig ; Nadine Roch ; Adriana Thomssen ; Thorsten Dohrmann ; Tung Yu Tsui ; Oliver Mann ; Jakob Robert Izbicki ; Yogesh Kumar Vashist ; ^{vashist@uke.de}
• 关键词：GNAS1 ; Polymorphism ; NSCLC ; Surgery ; Prognostic marker ; Relapse ; Survival
• 刊名：Lung Cancer
• 出版年：2013
• 出版时间：February, 2013
• 年：2013
• 卷：79
• 期：2
• 页码：151-155
• 全文大小：282 K

文摘

Introduction

The GNAS1 T393C single nucleotide polymorphism (T393C-SNP) correlates with G¦Ás mRNA stability and protein expression and augmented apoptosis. Genetic germ line variations as stable and reproducible markers potentially serve as prognostic marker in oncology. The aim of this study was to evaluate the potential prognostic value of T393C-SNP in complete resected non-small cell lung cancer (NSCLC).

Patients and methods

In total 163 Caucasian patients, who had been surgically treated for NSCLC between 1998 and 2010, were included in this study. Genotyping of peripheral blood cells was performed by polymerase chain reaction and digestion using the restriction enzyme FokI. The T393C-SNP was correlated with clinic-pathological parameters and survival. Chi-square test, Kaplan-Meier estimator and cox regression hazard model were used to assess the prognostic value of the T393C-SNP.

Results

C-allele carriers had a higher recurrence rate (p = 0.018) and a shorter disease-free survival compared to homozygous T-allele carriers (12.26 months vs. 44.65 months, p = 0.009). The overall survival in homozygous C allele carriers was shorter (19.10 months vs. 53.95 months, p = 0.019). Multivariate Cox regression identified the CC genotype as a negative independent prognostic factor for recurrence (hazard ratio 2.36, p = 0.007) and survival (hazard ratio 2.51, p = 0.008).

Conclusion

Determination of T393C-SNP preoperatively potentially allows allocation of NSCLC patients into different risk profiles and may influence the therapeutic strategy.